{
Jo Walton

People

}
novo nordisk faces stock plunge after disappointing results for obesity drug
Novo Nordisk's shares plummeted over 21% following disappointing results from the Phase 3 trial of its obesity drug CagriSema, which achieved a 22.7% average weight reduction, falling short of the expected 25%. Analysts have reacted with downgrades, citing safety concerns and underperformance compared to competitors. Despite achieving primary study objectives, the market's response reflects significant investor disappointment.
aktiencheck.de
Danish Krone Catalent, Inc. Novo Nordisk A/S Eli Lilly and Company DNK Florent Cespedes Emmanuel Papadakis Jo Walton Peter Welford Show more
Healthcare, Market Report
15:35 20.12.2024
ubs maintains neutral rating on novo nordisk amid disappointing weight loss data
UBS has maintained a "Neutral" rating for Novo Nordisk, setting a target price of 1,100 Danish crowns. Analyst Jo Walton highlighted disappointing results for the weight loss drug Cagrisema, which showed a 20.4% reduction, falling short of the expected 25%. Future focus may shift towards availability, tolerability, and convenience of oral administration rather than efficacy.
boerse.de
Danish Krone Novo Nordisk A/S Eli Lilly and Company DNK Jo Walton Show more
Healthcare, Market Report
15:17 20.12.2024
UBS Maintains Neutral Rating for Novo Nordisk with Target Price of 1100 Kroner
UBS has maintained a "Neutral" rating for Novo Nordisk, setting a target price of 1100 Danish kroner. Analyst Jo Walton noted a slight increase in first-time prescriptions for weight-loss drugs in the US, based on data up to December 6.
boerse.de
United States Dollar Danish Krone Novo Nordisk A/S DNK Jo Walton
Healthcare, Market Report
15:24 16.12.2024
UBS Maintains Neutral Rating for Novo Nordisk with 1100 Kroner Target
UBS has maintained a 'Neutral' rating for Novo Nordisk, setting a price target of 1100 Danish crowns. This decision reflects recent trends in prescription rates for weight-loss drugs in the USA, as noted by analyst Jo Walton in a study published on December 9, 2024.
MarketScreener
Danish Krone Novo Nordisk A/S DNK Jo Walton
TradFi, Market Report
17:19 09.12.2024
ubs maintains neutral rating for novo nordisk amid stagnant demand for wegovy
UBS has maintained a "Neutral" rating for Novo Nordisk, setting a target price of 1100 Danish kroner. Despite the reavailability of the weight loss drug Wegovy, analyst Jo Walton noted a lack of significant demand increase in the US market.
boerse.de
Danish Krone Novo Nordisk A/S DNK Jo Walton
TradFi, Market Report
15:13 02.12.2024
ubs maintains neutral rating for novo nordisk with target price of 1100 kroner
UBS has maintained a 'Neutral' rating for Novo Nordisk, setting a target price of 1100 Danish crowns. Despite the reavailability of the weight loss drug Wegovy, analyst Jo Walton noted a lack of significant demand increase in the USA.
MarketScreener
United States Dollar Danish Krone Novo Nordisk A/S DNK Jo Walton
TradFi, Market Report
15:00 02.12.2024
ubs lowers bayer price target to 22 euros maintains neutral rating
UBS has reduced its price target for Bayer from 30 to 22 euros while maintaining a "Neutral" rating. Analyst Jo Walton cited a weak outlook for the Leverkusen-based company, resulting in a 16% decrease in the earnings forecast for 2025.
finanzen.net
Euro Bayer DEU Jo Walton
TradFi, Market Report
16:58 21.11.2024
UBS Lowers Bayer Price Target to 22 Euros Maintains Neutral Rating
UBS has reduced its price target for Bayer from 30 to 22 euros while maintaining a "Neutral" rating. Analyst Jo Walton cited a weak outlook for the Leverkusen-based company, resulting in a 16% decrease in the earnings forecast for 2025.
boerse.de
Euro Bayer CHE DEU Thomas Müller Hubert Dichtl Jo Walton Warren Buffet Show more
TradFi, Market Report
07:26 21.11.2024
UBS cuts Bayer price target to 22 euros maintaining neutral rating
UBS has reduced its price target for Bayer from 30 to 22 euros while maintaining a "Neutral" rating, citing a weak outlook for the company. This adjustment reflects a 16% decrease in the earnings forecast for 2025. Bayer's sales are primarily derived from agricultural products (48.8%) and pharmaceuticals (38%).
MarketScreener
Euro Bayer AG CHN USA DEU BRA CHE Jo Walton Show more
TradFi, Market Report
07:13 21.11.2024
ubs maintains neutral rating for bayer with unchanged price target
UBS AG has maintained a "Neutral" rating for Bayer, with a price target of 30 euros, following insights from CFO Wolfgang Nickl at an investor conference. Despite Bayer shares dropping 3.2% to EUR 20.22, there remains a potential upside of 48.37%. The stock has declined 39.6% since the start of 2024, with Q4 2024 financial results expected on March 5, 2025.
finanzen.ch
Euro Bayer AG DEU Jo Walton Wolfgang Nickl
TradFi, Market Report
16:04 13.11.2024
Trending
Subcategory:
Cryptocurrency Markets Stock Market Updates Cryptocurrency Trends Market Sentiment Analysis Central Bank Actions Banking Regulations Corporate Responsibility & ESG Decentralized Finance (DeFi) Innovations Tokenomics and Crypto Economics Mergers & Acquisitions Cryptocurrency & Blockchain Regulations Cryptocurrency Developments Blockchain Technology Adoption Anti-Money Laundering (AML) Regulations Market Analysis and Predictions Emerging Startups Cryptocurrency Regulations Inflation Rates & CPI Data SEC & Financial Compliance Banking & Investment Regulations
Countries:
USA CHE GBR DEU ARE HKG AUS JPN IND CHN CAN SGP DNK NGA FIN COL AUT VGB LIE TUR
Companies:
Credit Suisse Real Estate Fund Siat BlackRock, Inc. Coinbase Global, Inc. Solana USD Ethereum USD Apple Inc. Ripples USD Tesla, Inc. Fidelity Contrafund Cardano USD NVIDIA Corporation Grayscale Litecoin Trust Chainlink USD Tether USDt CNY Google Inc. Amazon.com, Inc. MicroStrategy Inc Franklin Templeton - Franklin M End Federal Reserve USD MicroStrategy Incorporated
Currencies:
United States Dollar Euro Swiss Franc Japanese Yen Australian Dollar Indian Rupee Canadian Dollar Mozambican Metical British Pound Sterling Norwegian Krone Mongolian Tögrög Colombian Peso Singapore Dollar
People:
Donald Trump Ali Martinez Elon Musk Karin Keller-Sutter Jerome Powell Ueli Maurer Michael J. Saylor Thomas Jordan Gary Gensler Colm Kelleher Alan Santana Paul Atkins Joe Rogan Martin Schlegel Isabelle Chassot Mario Nawfal Paolo Ardoino Sergio Ermotti Dana White Joe Biden

MachinaCore is a highly modular and scalable system that allows users to build custom widgets and tools tailored to their specific financial data needs, while seamlessly integrating with other MachinaLabs products, like Machinary, MachinaAI Modules and MachinaTrader.

Links

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.